Aileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) major shareholder Of Texas/Texas Am I. University sold 10,746 shares of the business's stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $4.95, for a total transaction of $53,192.70. Following the transaction, the insider now directly owns 1,799,711 shares of the company's stock, valued at $8,908,569.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Aileron Therapeutics Trading Down 8.6 %
ALRN opened at $4.16 on Thursday. The firm's 50 day simple moving average is $5.43 and its two-hundred day simple moving average is $3.82. The company has a market capitalization of $70.60 million, a PE ratio of -1.23 and a beta of 2.22. Aileron Therapeutics, Inc. has a 1-year low of $1.01 and a 1-year high of $7.42.
Aileron Therapeutics (NASDAQ:ALRN - Get Free Report) last released its earnings results on Monday, April 15th. The company reported ($1.54) earnings per share for the quarter. Equities analysts forecast that Aileron Therapeutics, Inc. will post -0.62 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits | Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you?
In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants.
Absolutely no strings attached.
Secure Your Spot Now
Separately, LADENBURG THALM/SH SH upped their price objective on Aileron Therapeutics from $9.00 to $19.00 and gave the company a "buy" rating in a research report on Thursday, April 18th.
Get Our Latest Stock Report on Aileron Therapeutics
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Aileron Therapeutics stock. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 15,773 shares of the company's stock, valued at approximately $48,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.32% of Aileron Therapeutics at the end of the most recent reporting period. 90.89% of the stock is currently owned by institutional investors.
About Aileron Therapeutics
(
Get Free Report)
Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
